lymphoid malignancies certain solid cancers medullary thyroid carcinoma somewhat mixed success achieved applying radioimmunotherapy rit treatment refractory cases development novel rit created new opportunities theoretical advantages high linear energy transfer let short path length biological tissue physical properties offer prospect achieving selective tumoural cell killing rit appears particularly suited elimination circulating single cells cell clusters treatment micrometastases early stage avoid irradiation healthy tissues necessary identify accessible tumoural targets easily rapidly purpose small number investigated used vivo preclinical studies problem availability cost radionuclides instance low cost development reliable generator probably determining elements choice human trial rit article reviews literature concerning monoclonal antibodies radiolabelled developed possible rit cancer patients principal considered starting physical chemical properties mode production possibilities difficulties labelling vitro studies finally available vivo preclinical clinical studies references NUMBER beta emitters alpha emitters alpha particles alpha emitters non specific alpha emitters actinium NUMBER bismuth NUMBER alpha emitter alpha emitters radio immunoconjugates alpha emitters NUMBER bismuth